Anti-CD4 monoclonal antibody for relapsing polychondritis

Lubbe, PeterA. Van Der; Miltenburg, AndréM.; Breedveld, F. C.

doi:10.1016/0140-6736(91)93023-3

Cited by 42 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine (12), mycophenolate mofetil (13), and anti–tumor necrosis factor (anti‐TNF) (14) have been used for severe manifestations of refractory relapsing polychondritis with varying degrees of efficacy. Other therapies such as plasmapheresis, anti‐CD4 monoclonal antibodies (15), and autologous stem cell transplantation (16) have also been reported in a few cases.…”

Section: Introductionmentioning

confidence: 99%

Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients

Leroux¹,

Costédoat-Chalumeau²,

Brihaye³

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen expressed by B cells, is now considered an effective second-line therapy in various systemic diseases. We describe here the effects of rituximab in patients with relapsing polychondritis. Methods. This was a retrospective study of 9 patients with relapsing polychondritis who received different regimens of rituximab in addition to their ongoing therapies. Clinical, laboratory, physiologic, and radiologic indicators were used to assess disease activity. We also examined their corticosteroid doses and any change in immunosuppressive agents. We then compared disease activity in the 6 months preceding rituximab administration and at 6 and 12 months after. Results. At 6 months, 2 patients showed partial improvement, 4 were stable, and 3 had worsened disease; however, no patient had complete remission. At 12 months (after exclusion of the 3 patients whose disease had worsened at 6 months), 2 patients remained stable and 4 had worsened disease; however, there were no partial or complete remissions. B cells were counted in 8 patients during the first 6 months after treatment, and B cell depletion was observed in all of the patients. Conclusion. Although we cannot rule out the possibility that rituximab had a small effect, our patients' clinical courses did not improve significantly with this treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients

Leroux¹,

Costédoat-Chalumeau²,

Brihaye³

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Anti-CD4 monoclonal antibody was the first biological agent tried with some efficacy in RP [76,77]. There are isolated case reports of favourable response to rituximab in patients not responding to immunosuppressive therapy [78,79].…”

Section: Managementmentioning

confidence: 99%

Relapsing polychondritis: a review

et al. 2013

View full text Add to dashboard Cite

Relapsing polychondritis is a rare multisystem disease involving the cartilaginous and proteoglycan rich structures. The spectrum of clinical presentations may vary from intermittent episodes of painful and often disfiguring auricular and nasal chondritis, to occasional organ or even lifethreatening manifestations like airway collapse. There is lack of awareness about this disease due to its rarity. Relapsing polychondritis disease activity index has recently been validated and may help in clinical decision making and research. This article reviews the literature on this disease entity.

show abstract

“…Azathioprine, cyclophosphamide, Cyclosporin A, dapsone, and anti-CD4 monoclonal antibodies have been used in conjunction with steroids in these patients with variable success. 8,[13][14][15][16][17][18][19] Computed tomography (CT) has, in the last 10 years, been shown to be helpful in limiting the differential diagnosis. The findings are typically those of airway narrowing; thickening of the soft tissues lining the trachea, bronchi, and larynx; and calcification of the tracheal wall.…”

Section: Discussionmentioning

confidence: 99%

A new role for magnetic resonance imaging in the diagnosis of laryngeal relapsing polychondritis

1999

View full text Add to dashboard Cite

Background Relapsing polychondritis involving the upper airway is a rare cause of airflow obstruction and hoarseness. The diagnosis of relapsing polychondritis depends on clinical signs, characteristic findings on cartilage biopsy, and response to treatment. Delays in diagnosis and treatment can increase the morbidity and mortality of the disease. Methods We present a case report of primary laryngeal relapsing polychondritis. Results Serologic testing, direct laryngoscopy, and endoscopic biopsy could not establish the diagnosis of relapsing polychondritis. Magnetic resonance imaging (MRI) examination demonstrated findings consistent with the histopathological diagnosis obtained on open biopsy. Follow‐up MRI after treatment showed resolution of the initial findings. Conclusion This case demonstrates the usefulness of MRI in the diagnosis and management of relapsing polychondritis involving the upper airway. © 1999 John Wiley & Sons, Inc. Head Neck 21: 484–489, 1999.

show abstract

Anti-CD4 monoclonal antibody for relapsing polychondritis

Cited by 42 publications

References 3 publications

Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients

Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients

Relapsing polychondritis: a review

A new role for magnetic resonance imaging in the diagnosis of laryngeal relapsing polychondritis

Contact Info

Product

Resources

About